Adeno-Associated Viral Vectors Market Size, Emerging Trends, Growth Rate, Business Opportunities And Forecast To 2033

The new report published by The Business Research Company, titled "Adeno-Associated Viral Vectors Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $2.29 billion in 2023 to $2.69 billion in 2024 at a compound annual growth rate (CAGR) of 17.6%. The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $5.17 billion in 2028 at a compound annual growth rate (CAGR) of 17.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

Rising Prevalence Of Genetic Disorders Fuels Growth In The Adeno-Associated Viral Vectors Market
The increasing prevalence of genetic disorders is expected to propel the growth of the adeno-associated viral vectors market going forward. Genetic disorders are conditions caused by abnormalities in an individual's DNA, leading to physical or developmental abnormalities. The improved diagnostic techniques, greater awareness, and higher reproductive age, along with environmental factors and genetic drift are leading to the rise in the prevalence of genetic disorders. Adeno-associated viral vectors are utilized in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat conditions like muscular dystrophy or cystic fibrosis. For instance, in February 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital diseases caused an estimated 240,000 baby deaths globally within 28 days of birth each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases. Therefore, the increasing prevalence of genetic disorders is driving the adeno-associated viral vectors market.

Advancements In Off-the-Shelf Rep/Cap Plasmids
Major companies operating in the adeno-associated viral vectors market are focusing on offering off-the-shelf availability of replication-capsid plasmid to gain a competitive edge in the market. Rep/Cap plasmids, commonly utilized in gene therapy for adeno-associated virus (AAV) vector production, are readily available from numerous commercial suppliers catering to molecular biology research needs. For instance, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced off-the-shelf replication-capsid plasmid range streamlines AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, cutting manufacturing efforts by as much as 66%. These ready-to-use plasmids undergo batch production with meticulous documentation, adhering to CMC guidelines and accompanied by Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.

The adeno-associated viral vectors market covered in this report is segmented -

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15969&type=discount

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Contents of the report:
1. Executive Summary
2. Adeno-Associated Viral Vectors Market Report Structure
3. Adeno-Associated Viral Vectors Market Trends And Strategies
4. Adeno-Associated Viral Vectors Market - Macro Economic Scenario
5. Adeno-Associated Viral Vectors Market Size And Growth
…..
27. Adeno-Associated Viral Vectors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.